Last reviewed · How we verify
NOAC+DAPT
NOAC+DAPT, developed by Zunyi Medical College, is a marketed small molecule combining a NOAC and DAPT mechanism, positioned in the anticoagulant and antiplatelet therapy market. The drug's key strength lies in its unique dual-action mechanism, which may offer enhanced efficacy and safety compared to monotherapy options. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | NOAC+DAPT |
|---|---|
| Also known as | Rivaroxaban + ticagrelor or clopidogrel + aspirin |
| Sponsor | Zunyi Medical College |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SIMPLAAFY Clinical Trial (NA)
- The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models (NA)
- Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF (PHASE3)
- Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease (NA)
- Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus (PHASE4)
- What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? (PHASE4)
- Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion (PHASE4)
- Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NOAC+DAPT CI brief — competitive landscape report
- NOAC+DAPT updates RSS · CI watch RSS
- Zunyi Medical College portfolio CI